

University of Texas Rio Grande Valley

ScholarWorks @ UTRGV

---

School of Medicine Publications and  
Presentations

School of Medicine

---

7-7-2022

## Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review

Kizil A. Yusoof

Juan Ignacio Garcia

Alyssa Schami

Andreu Garcia-Vilanova

Holden V. Kelley

*See next page for additional authors*

Follow this and additional works at: [https://scholarworks.utrgv.edu/som\\_pub](https://scholarworks.utrgv.edu/som_pub)



Part of the [Medicine and Health Sciences Commons](#)

---

---

**Authors**

Kizil A. Yusoof, Juan Ignacio Garcia, Alyssa Schami, Andreu Garcia-Vilanova, Holden V. Kelley, Shu-Hua Wang, Adrian Rendon, Blanca I. Restrepo, Marcel Yotebieng, and Jordi B. Torrelles



# Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnosics: A Review

Kizil A. Yusoof<sup>1†</sup>, Juan Ignacio García<sup>2\*†</sup>, Alyssa Schami<sup>1,2</sup>, Andreu Garcia-Vilanova<sup>2</sup>, Holden V. Kelley<sup>2</sup>, Shu-Hua Wang<sup>3</sup>, Adrian Rendon<sup>4</sup>, Blanca I. Restrepo<sup>5,6\*</sup>, Marcel Yotebieng<sup>7\*</sup> and Jordi B. Torrelles<sup>1,2\*</sup>

## OPEN ACCESS

### Edited by:

Harriet Mayanja-Kizza,  
Makerere University, Uganda

### Reviewed by:

María Teresa Tórtola Fernández,  
Vall d'Hebron University Hospital,  
Spain

Wondwossen Amogne Degu,  
Addis Ababa University, Ethiopia

### \*Correspondence:

Juan Ignacio García  
juangarcia@txbiomed.org  
Blanca I. Restrepo  
Blanca.I.Restrepo@uth.tmc.edu  
Marcel Yotebieng  
marcel.yotebieng@einsteinmed.org  
Jordi B. Torrelles  
jtorrelles@txbiomed.org

<sup>†</sup>These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Microbial Immunology,  
a section of the journal  
Frontiers in Immunology

Received: 07 February 2022

Accepted: 06 June 2022

Published: 07 July 2022

### Citation:

Yusoof KA, García JI, Schami A,  
García-Vilanova A, Kelley HV,  
Wang S-H, Rendon A, Restrepo BI,  
Yotebieng M and Torrelles JB (2022)  
Tuberculosis Phenotypic and  
Genotypic Drug Susceptibility Testing  
and Immunodiagnosics: A Review.  
*Front. Immunol.* 13:870768.  
doi: 10.3389/fimmu.2022.870768

<sup>1</sup> Graduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, TX, United States,

<sup>2</sup> Population Health Program, Tuberculosis Group, Texas Biomedical Research Institute, San Antonio, TX, United States,

<sup>3</sup> Department of Internal Medicine, Division of Infectious Diseases, College of Medicine and Global One Health Initiative, The Ohio State University, Columbus, OH, United States, <sup>4</sup> Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias (CIPTIR), Hospital Universitario de Monterrey Universidad Autónoma de Nuevo León (UANL), Monterrey, Mexico, <sup>5</sup> School of Public Health, University of Texas Health Science Center at Houston, Brownsville, TX, United States,

<sup>6</sup> School of Medicine, South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Edinburg, TX, United States, <sup>7</sup> Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, New York City, NY, United States

Tuberculosis (TB), considered an ancient disease, is still killing one person every 21 seconds. Diagnosis of *Mycobacterium tuberculosis* (*M.tb*) still has many challenges, especially in low and middle-income countries with high burden disease rates. Over the last two decades, the amount of drug-resistant (DR)-TB cases has been increasing, from mono-resistant (mainly for isoniazid or rifampicin resistance) to extremely drug resistant TB. DR-TB is problematic to diagnose and treat, and thus, needs more resources to manage it. Together with+ TB clinical symptoms, phenotypic and genotypic diagnosis of TB includes a series of tests that can be used on different specimens to determine if a person has TB, as well as if the *M.tb* strain+ causing the disease is drug susceptible or resistant. Here, we review and discuss advantages and disadvantages of phenotypic vs. genotypic drug susceptibility testing for DR-TB, advances in TB immunodiagnosics, and propose a call to improve deployable and low-cost TB diagnostic tests to control the DR-TB burden, especially in light of the increase of the global burden of bacterial antimicrobial resistance, and the potentially long term impact of the coronavirus disease 2019 (COVID-19) disruption on TB programs.

**Keywords:** TB diagnostics, multi-drug resistance, anti-TB drug regimens, active TB, point of care (POC)

## INTRODUCTION

The World Health Organization (WHO) estimates that over the next 35 years, without proper surveillance and diagnosis, approximately 75 million people will suffer from drug resistant (DR)-tuberculosis (TB), costing the global economy \$16.7 trillion dollars (1, 2). These numbers may fall short due to the projected negative impact of the coronavirus disease 2019 (COVID-19) pandemic on TB control. For decades, the WHO has relied on a simplified and pragmatic approach offering

standardized drug regimens to everyone to treat TB. However, the control and management of the rising burden of DR-TB requires universal access to drug susceptibility testing (DST) and individualized treatment approaches. Currently, in high TB burden countries, there are limited diagnostic options to test for DR-TB. Tests such as the BACTEC<sup>TM</sup> Mycobacteria Growth Indicator Tubes (MGIT), Xpert or Xpert Ultra<sup>®</sup> MTB/RIF, Truenat MTB/MTB Plus/MTB-RIF DX, and Line Probe Assays (LPA), although provide results for DR-TB, are costly and require complex equipment, laboratory infrastructures, biosafety needs, and training for lab technicians. These facts limit their deployment in point of care (POC) settings in low resource communities, where DR-TB cases are rising, specially due to the impact of the COVID-19 pandemic limiting DR-TB testing and treatment (lack of drug supplies), and dedicated personnel (3). Thus, there is a need to develop improved POC diagnostic tests for prompt DR-TB diagnosis and treatment monitoring.

Despite the substantial progress in overall TB control that resulted in a 47% decrease in TB mortality between 1990 and 2015, TB still remains as one of the single infectious diseases associated with high mortality (4). The emergence of several profiles of DR-TB over the past 30 years has further complicated the use of standardized drug treatment regimens. Even pre-COVID-19, estimates indicated that DR-TB will be responsible for more deaths due to antimicrobial resistance than any other single pathogen (5).

Halting the burden of DR-TB will require access to high quality drug susceptibility testing to inform and guide individualized regimens for every TB patient, particularly in high-burden low resource settings. Here, we review the current diagnostic landscape for DR-TB including those in development to assess their suitability and sustainability for DR-TB control based on individualized regimens. Importantly, we explore the possibility of applying known serological test for active TB, as well as to determine if a given patient is responding to treatment. The need for specific *M.tb* and/or host biomarkers to differentiate drug-susceptible (DS) and DR-TB with a simple POC test is also discussed.

## UPDATED DR-TB DEFINITIONS

Since the early 1990s, TB prevention and care have been complicated by the growing global burden of rifampicin-resistant (RR) and multidrug-resistant (MDR)-TB. MDR-TB is defined as infection with *M.tb* resistant to at least the first line drugs isoniazid (INH) and rifampicin (RIF) (6). Recently, a WHO expert consultation meeting updated the definitions for extensively-drug resistant (XDR-TB) (7); since January 2022, pre-XDR-TB is defined as TB caused by *M.tb* strains that fulfill the definition of MDR/RR-TB and that are also resistant to any fluoroquinolone, and XDR-TB is defined as TB caused by *M.tb* strains that fulfill the definition of MDR/RR-TB and that are also resistant to any fluoroquinolone and at least one additional Group A drug. The Group A drugs are currently levofloxacin or moxifloxacin, bedaquiline and linezolid; therefore, XDR-TB is

MDR/RR-TB that is resistant to a fluoroquinolone and either bedaquiline or linezolid, or both (7). Further, the terms, extremely-drug-resistant TB (XXDR-TB) and total-drug-resistant TB (TDR-TB) were proposed by specific studies to describe the cohort of patients resistant to all tested anti-TB drugs (8–11). However, these terms are not recognized by the WHO as DST is technically challenging and cannot be thoroughly tested since current drug effectiveness against TDR strains are not extensively reported (10). XXDR-TB refers to strains that are resistant to all first and second line anti-TB drugs (8). XXDR resistance, although difficult to treat, is distinct from TDR-TB. TDR-TB is reserved for *M.tb* strains that demonstrate resistance to all available first- and second-line anti-TB drugs, including drugs in the discovery pipeline (9). This drug resistance is thought to be attributed to bacterial chromosomal mutations, inadequate treatments, lengthy drug regimens, patient non-compliance, and presence of other comorbidities, among other reasons (12, 13).

In the last 15 years, while the numbers of deaths due to DS- and DR-TB are estimated to have declined by 20.6% and 28.9%, respectively, deaths due to pre-XDR/XDR-TB have significantly increased by 67.6% (14). Indeed, cases of natural polymorphisms in *M.tb* conferring resistance to the newest anti-TB drug delamanid in drug-naïve patients are reported in countries where this drug had not yet been introduced (15). Similarly, discordant results between laboratories testing the same patient's sample, different patient's samples, and/or between genotypic and phenotypic testing of the same sample, add a layer of complexity to the already difficult task of identifying and properly classifying DR-TB. In this context, in a recent study looking at mortality among people with TB living in various settings across the globe, researchers compared phenotypic or genotypic DS-TB test results obtained from both local and a Switzerland reference laboratories testing identical samples (16). Discordant results were found between local and reference laboratories in about 20% of the samples assessed. Mortality ranged from 6% in people with pan-susceptible TB treated according to WHO guidelines, to 57% in people with DR-TB who went under-wrong treatment because of the discordance between both the local and reference laboratories (16). Interestingly, people with INH mono-resistant TB, the most common form of DR-TB globally, had a higher mortality rate compared to MDR-TB patients (16). Thus, in order to reduce TB mortality among DR-TB patients timely access to accurate DST is essential for every TB patient to inform and guide the therapeutic decision.

## CURRENT LANDSCAPE FOR UNIVERSAL DST

### Phenotypic DST

WHO recommends rapid diagnostics and universal DST (at least RIF resistance testing) for all people experiencing clinical symptoms of active TB, although the current available tools make this goal impossible (17, 18). There are a number of genotypic and phenotypic DST diagnostic tools available for

DR-TB diagnosis; however, their optimal use and their results interpretation are critical for a timely and accurate DR-TB diagnosis to enable an effective patient treatment and care (19).

Among the phenotypic DST used for DR-TB diagnosis, culture, both solid and liquid, is the most commonly used method. Thus, a confirmed *M.tb* specimen is further cultured in solid or liquid media containing the critical concentration of a given anti-TB drug. Lack of *M.tb* growth indicates susceptibility to a given drug, while *M.tb* growth indicates resistance. Culture also provides information on the critical and the minimum inhibitory concentrations (MIC), where MIC is the lowest anti-TB drug concentration capable of inhibiting the growth of a *M.tb* strain.

Phenotypic DST in solid medium is standardized and the most frequently used form of DST in mid and low-income areas endemic for TB (Table 1). Löwenstein-Jensen (LJ) slants is the most widely used medium followed by Middlebrook (M) 7H10 or 7H11 agar (20). *M.tb* growth is visualized by the typical rough

colonies and cording formations. The indirect proportion method is the most commonly used for solid medium DST using a standardized and two 10-fold diluted dilutions of the inoculum with the anti-TB drug MIC tested (21). Drug resistance is defined when at least 1% of growth is observed at the drug MIC when compared to growth without drug. In many cases, due to the need to obtain enough bacterial growth for DST, specimens are first grown in LJ cultures and only after growth is detected the DST is performed. This considerably delays DST results, which can take 28–42 days or longer to obtain and report.

For phenotypic DST in liquid medium, liquid medium Middlebrook (M)7H9 or M7H10 broths are normally used for mycobacterial growth indicator tube (MGIT) automated *M.tb* culture system [Becton Dickinson and Company (BD) Diagnostic Systems, Sparks, MD, USA]. A specimen is added to the MGIT in the presence of a given concentration of anti-TB drug. Bacterial growth is detected automatically by fluorescence due to oxygen consumption by the presence of *M.tb*, indicating

**TABLE 1 |** Drug susceptibility tests for implementation in mid and low-income countries with high TB burden.


	TB technology test	Method principle	Cost <sup>#</sup>	Setting to be used	Turnaround time	Complexity	Point-of-care potential	WHO endorsed
Phenotypic DST*	BACTEC 460/960	Liquid culture	\$\$\$	Reference lab	10-42 days	High	No	Yes
	Löwenstein-Jensen	Solid culture	\$	Peripheral lab	30-45 days	Moderate	No	Yes
	7H10/7H11 agar	Solid culture	\$	Peripheral lab	21-28 days	Low	No	Yes
	1G/2G Color plates	Solid culture	\$	Peripheral lab	14-21 days	Low	No	No
Genotypic DST test	GeneXpert MTB/RIF	qPCR	\$\$\$	District lab	<2h	Low	Yes, if availability of GX-Edge or Omni platforms	Yes
	GeneXpert MTB/RIF Ultra	qPCR	\$\$\$	District lab	<2h	Low	Yes, if availability of GX-Edge or Omni platforms	Yes
	GeneXpert MTB/XDR**	qPCR	\$\$\$	District lab	1.5h	Low	Yes, if availability of GX-Edge or Omni platforms	Yes
	TB-LAMP	Loop-mediated isothermal amplification	\$\$\$	Peripheral lab	2h	Low	Yes	Yes
	GenoType MTBDRplus (1st line LPA)	PCR, hybridation	\$\$	Reference lab	5h	Moderate	No	Yes
	GenoType MTBDRs (2nd line LPA)	PCR, hybridation	\$\$	Reference lab	5h	Moderate	No	Yes
	FluoroType MTB and FluoroType MTBDR**	PCR, hybridation	\$\$	Reference lab	2.5h	Moderate	No	Yes
	Genoscholar PZA-TB**	PCR, hybridation	\$\$	Reference lab	1 day	Moderate		Yes
	Truenat MTB Plus	Micro RT-PCR	\$\$	Peripheral lab	2h	Low	Yes, onTruelab platform	Yes
	Truenat MTB-Rif Dx	Micro RT-PCR	\$\$	Peripheral lab	2h	Low	Yes, onTruelab platform	Yes
	Next generation sequencing (NGS)	Gene sequencing (WGS, GWAS)	\$\$\$	Reference lab	5-10 days	High	No	
	Abbott RealTime MTB**	PCR	\$\$\$	Reference lab	11.25h	Moderate	No	Yes
	Abbott RealTime MTB RIF/INH**	PCR	\$\$\$	Reference lab	11.25h	Moderate	No	Yes
Cobas MTB and cobas MTB-RIF/INH**	PCR	\$\$\$	Reference lab	4.5h	Moderate	No	Yes	

\*Additional phenotypic assays include, microscopically observed drug susceptibility assay (MODS), and colorimetric redox indicator (CRI).

\*\*Last recommendations from WHO consolidated guidelines on rapid diagnostics for TB detection, 2021.

<sup>#</sup>Costs are indicative using the range \$-\$\$\$ and includes set up, per test costs, and maintenance needs.

\$, Low cost; \$\$, Medium cost; \$\$\$, High cost.



that *M.tb* is present and it is resistant to the given drug being tested. MGIT DST is quicker than solid media, and it can take up to 14 to obtain results.

For first-line agents (INH/RIF) and some second-line anti-TB drugs [KAN, AMK, ofloxacin (OXO), levofloxacin (LEV)], phenotypic DST is generally consistent, reproducible, and widely used, except for pyrazinamide (PZA), which requires technical expertise to avoid high rates of false positive resistance using MGIT (20). Other anti-TB drugs such as fluoroquinolones [moxifloxacin (MOX), gatifloxacin], cycloserine, capreomycin, ethionamide and prothionamide, as well as re-purposed drugs clofazimine and linezolid are gaining importance to treat DR-TB, and thus, their concentrations for solid DST need to be consistently reevaluated and standardized worldwide. Further, new drugs for MDR-TB treatment such as bedaquiline and delamanid are recommended for use by WHO

under specific conditions and may be added to a core MDR-TB regimen (22), and thus their phenotypic DST reevaluation will be also a priority. This is critical as although phenotypic DST is considered by many a step backwards to improve DR-TB testing, there is evidence that show that INH- and RIF resistant TB cases are missed when using genotypic DST, resulting in misleading treatments (23). This is mainly due to the fact that genotypic DST can miss the detection of novel resistance-conferring mutations that are otherwise detected by phenotypic DST (24–29).

In order to improve phenotypic DST and make it more affordable and reliable in mid and low-income countries with high TB burden rates, our group has participated in the field testing of the first generation (1G) Color Plate (1G test) (30), an inexpensive and simple diagnostic that requires minimal training (31–34). The 1G test is a non-commercial test that is based on the



thin-layer agar (TLA) method with an added compound, 2,3-diphenyl-5-(2-thienyl) tetrazolium chloride (STC), that serves as an oxidation-reduction indicator that results in red *M.tb* colonies. This facilitates the detection of colonies isolated from sputum samples to diagnose active TB disease (31–34). Detection of *M.tb* using TLA has been effective for several years, is relatively inexpensive, and only requires an incubator and a 5-10X magnifier glass to confirm diagnosis (30). The 1G test can be used in rural health facilities where access to other molecular TB tests may be limited (34). This DST diagnostic test is used to identify the *M.tb* complex and detection of resistant strains to drugs such as INH, RIF, and ciprofloxacin (CIP) or PZA (30, 32, 34).

The 1G test requires minimum training, and has high sensitivity and specificity (32). Due to the STC indicator and special agar composition, *M.tb* growth is accelerated (detection in ~14 days), contaminations minimized, and colonies are visualized as red dots to the naked eye (30, 32, 34). This provides a simple concurrent readout of whether sputum samples are 1) positive for *M.tb* and 2) identification of drug resistance. The 1G test is divided into four quadrants in which one quadrant detects growth of *M.tb* (susceptible quadrant, no drug) and the other three quadrants detect drug resistance to INH, RIF, and CIP (30) (**Figure 1**). Since the 1G test has been an effective diagnostic tool for TB in rural areas such as Malawi and Ethiopia (31, 32, 34), our next step has been to expand the number of drug resistances that we can detect. Thus, we just expanded the 1G test from a quadrant culture-based test to a 12-well culture, which will provide drug resistance evaluation for 11 drugs (**Figure 1B**). This so-called 2<sup>nd</sup> Generation Color Plate test (2G test) can be used to: i) diagnose primary DS- or DR-TB; and ii) monitor the treatment success of DS- and DR-TB cases. The 1G test can be used only as a diagnostic test for DS-TB and as mono-resistant to INH or RIF, MDR, or pre-XDR); however, it could not track treatment success. The purpose of the 2G test is to gauge for drug resistance and to track the progression of the treatment response. This is particularly important to provide an accurate initial diagnosis and further track and update treatment plans for patients failing their initial treatment regimen. Currently, the 2G test is under field assessment with two types of test: an initial diagnostic test (2G DX), and a treatment progression monitoring test (2G TX) designed to monitor DR-TB patient treatment evolution. Drug composition for both 2G DX and 2G TX is depicted in **Figure 1B**, including the latest anti-TB drugs to treat DR-TB.

## Genotypic DST

Genotypic DST detects specific DNA mutations associated with resistance to specific anti-TB drugs in the *M.tb* genome. Genotypic DST has many advantages, including fast results, testing standardization and high throughput. However, the need of funding to support expensive equipment and supplies, a maintenance plan and quality assurance, specialized labs, and an uninterrupted electrical supply, as well as, an excessive cost per test, holds genotypic DST for being implemented globally for the management of DR-TB, especially in mid- and low-income regions with high TB incidence.

The development and implementation of nucleic acid amplification tests (NAATs) have revolutionized the TB and RR/MDR-TB field. As NAATs detect *M.tb* DNA in specimens, their performance correlates directly with the quality of the specimen tested. In the last update for rapid diagnostics for TB detection, WHO endorses three NAAT classes for genotypic DST: low, moderate and high based on the type of technology (automated or hybridization), target conditions (DS-, DR-TB), and complexity for its implementation (equipment, training, infrastructure) (18). Examples of low complexity tests include the Xpert MTB/RIF Ultra or Xpert XDR (Cepheid, Sunnyvale, CA, USA). Moderate complexity automated tests include the Abbott RealTime MTB and RealTime MTB RIF/INH (by Abbott, Abbott Park, Illinois, USA), FluoroType MTBDR and FluoroType MTB (by Hain Lifescience, Nehren, Germany), BD MAX<sup>TM</sup> MDR-TB (by BD, Franklin Lakes, New Jersey, USA), cobas MTB and cobas MTB-RIF/INH (by Roche, Basel, Switzerland) among others. High complexity tests include hybridization based tests such as the Genoscholar PZA-TB (Nipro Corporation, Tokyo, Japan) (18).

Current molecular testing of the first line drugs INH and/or RIF includes the Xpert and commercial line probe assays (LPAs), such as the Nipro NTM + MDRTB detection kit 2 (Nipro Corporation, Tokyo, Japan) and the MTBDRplus assay (Hain Lifescience, Nehren, Germany). The Xpert assay targets the detection of *M.tb* as well as detection of those mutations that confer RIF resistance. As this drug is rarely resistant by itself, RIF resistance (mutations in the *rpoB* gene) is used as a surrogate to define MDR-TB. The detection of RR *via* Xpert compares well with phenotypic DST methods (35). An advantage of LPAs is that these detect both INH and RIF associated mutations. INH resistance conferring mutations are defined in *inhA* (giving low resistance) and *KatG* (giving high resistance) and these account for ~90% of INH resistance as detected using phenotypic DST (36–39). The other ~10% of INH resistance is related to undetermined mutations in the *M.tb* genome, although mutations on *inhA* promoter and coding regions are reported to drive this resistance (40–43).

As a genotypic DST, in settings that can afford it, Xpert is used for initial diagnostic test for all people presented with TB compatible symptoms, followed by, in some cases, phenotypic DST such as culture. Xpert can be performed using both pulmonary and extrapulmonary specimens. Further, the Xpert Edge is now deployed with the goal of being more user friendly, as well as reducing testing cost and enhance efficiency, with a battery support to reach rural areas in need. Indeed, the Xpert XDR-TB is in development to fit the GeneXpert and GeneXpert Edge platforms to simultaneously detect mutations related to INH, fluoroquinolones, and 2<sup>nd</sup> line anti-TB agents (18, 44, 45). However, future studies will need to focus on the mechanism(s) of resistance behind the new generation of drugs developed or repurposed such as bedaquiline, delamanid, pretomanid, and linezolid among others, in order to develop novel molecular tests to capture *M.tb* developed resistance to these drugs. Nonetheless, the costs of Xpert technology is prohibited for many high TB burden countries, were cartridge supplies cost depend on owning

or leasing the instrument, varying from ~\$10 (own instrument) to \$100 (for leased instruments, with variations depending on the country) (46, 47), making many health centers to dismiss its use. Further, patients with previous TB may have residual DNA in sputum making Xpert prone to false-positive results (28, 48) that together with its suboptimal sensitivity in special populations such as children, people living with HIV (PLWH) and extrapulmonary TB patients (49, 50) has undermined its impact in long-term patient outcomes (51, 52). However, this technology is evolving and the possibility of generating a multi-array to diagnose co-infections may make the Xpert more cost-effective in the future. This is already thought for dual TB/COVID-19 testing, especially after the deployment of the Xpert Xpress SARS-CoV-2, which can also minimize the impact of using current Xpert equipment to diagnose only COVID-19 in detriment of TB (44).

The Truenat MTB tests (MTB, MTB plus and MTB-RIF Dx) developed by Molbio diagnostics Pvt. Ltd (Bangalore, India) are chip-based real time micro PCR detection assays for diagnosing TB. These tests can be deployed at peripheral health care settings with minimal infrastructure and depend on battery operated devices that extract, detect and amplify DNA from patient sputum samples for detection of DS- and RR-TB. WHO recommends these assays to be used as a diagnostic test for TB rather than smear microscopy/culture (53). An ongoing multicenter prospective clinical evaluation study in 19 clinical sites, shows good diagnostic accuracy results, despite some evidence of imprecision and inconsistency for sensitivity results and the need of more studies to evaluate the affordability and cost-effectiveness of its implementation (53, 54).

First line LPAs (FL-LPAs) for detection of INH/RIF resistance, as well as second-line LPAs (SL-LPAs) for the detection of resistance to second-line injectable drugs (mutations in the *rrs* and *eis* promoter genes) and fluoroquinolones (mutations in the *gyrA* and *gyrB* genes) are also commercially available (18). WHO recommends the use of commercial LPAs as a rule-out test for XDR-TB. However, caution is recommended because the detection of mutations in the *rrs* and/or *eis* genes by SL-LPA does not mean that the tested *M.tb* strain is resistant to all the drugs within the second line injectable drug class. Further, although a positive LPA result is reliable in smear positive sputum samples, its diagnostic performance in smear negative sputum samples is low, and thus, adopting LPA does not eliminate the need for phenotypic DST capacity, especially in regions with high DR-TB incidence (18, 55, 56). Another limitation for LPA wide implementation is the need of high-standard molecular facilities to perform the test, which makes its implementation highly challenging in many mid- and low income high TB burden regions (18, 44).

Like the Xpert and LPA, other NAATs are the Gen-Probe MTD test (57) and Pyrosequencing (PSQ) (58). Although there is a push for NAATs becoming a standard diagnosis practice for all presumptive TB cases (59), WHO recommends that NAAT must not replace phenotypic DST such as culture or MGIT. A positive NAAT result is recommended to be supported by other tests

such as culture, as well as a negative NAAT result should not be used to definitely exclude TB. Overall, increased use of NAAT in DR-TB diagnosis could decrease the time-to-treatment initiation; however, differential implementation, cost and access to NAAT is a limitation in high TB burden communities.

Although still far away from its routine implementation in the field, next generation sequencing technologies (NGS) (60), such as whole-genome sequencing (WGS) of *M.tb* followed by association with phenotypic resistance using genome-wide association studies (GWAS) are also promising tools for the diagnosis of DR-TB (61, 62). Indeed, GWAS has been used for both, identification of host and *M.tb* traits implicated in the evolution of DR-TB. Thus, host GWAS studies have identified polymorphisms correlated to the heritability of host susceptibility to TB (63), as well as, *M.tb* GWAS studies revealed new resistance genes and regulatory regions implicated in the *M.tb* resistance to 11-anti-TB drugs (64). Some of the advantages of WGS-based diagnostic strategies (65) is the accuracy to diagnose DR-TB (66); however, due to much higher costs compared to traditional microbiological techniques and the need for computing and bioinformatics capabilities, NGS in resource-constrained settings is still far from being implemented (7).

Currently, several novel molecular tests for TB detection are under development at different levels of care: from reference labs to decentralized health care settings to be used as POC tests (18). Although not WHO endorsed yet, the Xpert GX-Edge and Omni, WGS, POC NAATS, and centralized DST can add to the current WHO endorsed LPA, Xpert, TB-LAMP, and Truenat to diagnose DS- and DR-TB, although caution needs to be considered for some of these tests as there is very low certainty of evidence for test accuracy for some of them in determining DR-TB (e.g. Truenat by Molbio) (67–69). For detailed current molecular diagnostic tests in the pipeline (e.g. POC NAATs such as Q-POC from QuantuMDx, indigenous Chinese diagnostics, high-throughput centralized diagnostic test, and next generation sequencing) see the review by MacLean *et al.* elsewhere (44).

## TB IMMUNODIAGNOSTIC TESTS

### Immunodiagnosics of Latent *M.tb* Infection (LTBI)

A challenge to TB control worldwide is being able to identify the individuals who are going to progress to develop active TB disease upon infection. Targeting these individuals for latent *M.tb* infection (LTBI) treatment can substantially reduce active TB risk. Thus, testing for LTBI is indicated when the risk of developing disease is increased, such as recent contacts of new TB patients, or anyone with a potential exposure that has compromised capacity to contain the infection due to altered immunity (70). These include PLWH, poorly-controlled diabetes, taking immunosuppressive medications (e.g. steroids), young (infants and children) or old age, and other conditions including malnutrition (71, 72). Thus, it is important to identify these individuals, but there is no diagnostic gold standard for



LTBI, and particularly for those with high risk of developing active TB.

Two types of LTBI screening tests are available: the tuberculin skin test (TST) and interferon gamma (IFN- $\gamma$ ) release assays (IGRAs). They represent indirect markers of LTBI based on immunological memory of T lymphocytes to *M.tb* antigens. These tests have an acceptable performance and are widely used in the clinical setting, but have limitations: Neither has a gold standard for confirmation of LTBI, they cannot distinguish LTBI from active TB, nor the various stages of the spectrum of LTBI, and they have a low positive predictive value (about 2-3%) for progression from LTBI to active TB disease (73).

The TST consists of the intradermal injection of mycobacterial purified protein derivative (PPD), with recall immunity inducing a delayed-type hypersensitivity measured by local induration approximately 48 h post-administration (74). Limitations include false positives due to cross-reactivity with non-tuberculous mycobacteria (NTM) and possibly with BCG-vaccinated individuals, particularly if re-vaccinated after infancy and multiple times (72). Specificity is 97% in regions where BCG vaccination is not used, and lowers to about 60% in regions where BCG is applied (75, 76). False negatives occur in patient groups who are immunosuppressed (e.g. HIV, malnutrition) or the elderly due to reduced intradermal immunity (72, 77).

IGRA tests are based on the detection IFN- $\gamma$  production by peripheral blood lymphocytes in response to specific peptides from *M.tb*, mostly early secretory antigenic target protein (ESAT)-6 and culture filtrate protein (CFP)-10. These peptides are more specific than PPD antigen because they are not encoded in the genomes of most other mycobacteria, with assays reaching >95% specificity. IGRAs are conducted ex-vivo after a blood draw, and hence, only require one office visit. There are two commercial IGRA: The T-SPOT.TB<sup>®</sup> (Oxford Immunotec Ltd, Abingdon, United Kingdom) and the QuantiFERON<sup>®</sup>, which has had several versions, with the current being the QuantiFERON-Gold Plus (QFT-Plus; Qiagen, Germantown, MD, USA) (74). The T-SPOT.TB is an enzyme-linked immunosorbent spot assay, while the QuantiFERON uses an ELISA format. The sensitivity of the T-SPOT.TB is generally higher compared to QuantiFERON or TSTs (approximately 90%, 80% and 80%, respectively), but this will vary between study populations. Further, although IGRA is a useful diagnostic method for differentiating TB from NTM diseases, in China for example (78), IGRA shows limited value in this discrimination (79). Further, IGRA does not differentiate *M.tb* from *M. kansasii*, *M. szulgai*, and *M. marinum* because these mycobacterial species also have ESAT-6 and CFP-10 (78, 80). Among the elderly both IGRAs perform similarly, which contrast with the reduced sensitivity of TST in this population (77).

In recent years, the focus has shifted to improving the specificity of immunodiagnosics to identify active TB disease vs. LTBI. Certain studies have investigated the diagnosis of active TB using multiplex cytokine and chemokine analysis to improve

the sensitivity of IGRAs (81–83). Alternatively, the focus is on depicting *M.tb*-specific T-cell responses *via* flow cytometry measuring both phenotype and function of the T cells (84). Other options used the QuantiFERON-TB Gold In-Tube (QFT-GIT) supernatant in people with and without HIV co-infection, to increase the specificity for active TB diagnosis vs. LTBI by looking at differences in multiple host cytokine and chemokine biomarkers assessing multiple unstimulated cytokine/chemokines (IFN- $\gamma$ , MIP-1 $\beta$ , and TGF- $\alpha$ ) coupled with stimulated cytokines (TGF- $\alpha$  and VEGF) (84, 85).

Assessing the activation of *M.tb*-specific T cells is an active field to develop TB immunodiagnosis, for example looking at CD4<sup>+</sup> IFN- $\gamma$ <sup>+</sup> T cells for HLA-DR, CD38, and Ki-67 markers, which shows 100% sensitivity and 95% specificity for active TB (86–88). Phenotypic changes on *M.tb*-specific CD4 T cells are also used as surrogate markers for TB treatment efficacy and can help to discriminate between TB (profile: CD38<sup>pos</sup>, CD27<sup>low</sup>), treated TB (CD38<sup>neg</sup>, CD27<sup>low</sup>), and LTBI (CD38<sup>neg</sup>, CD27<sup>high</sup>) (89). Other studies have looked at *M.tb*-specific TNF producing CD4<sup>+</sup> T cells along with the detection of *M.tb*-specific CD8<sup>+</sup> T cells and found that, in combination, these immunological assays have a 81.1% sensitivity and 86.5% specificity in the diagnosis of active TB (90–92). Active TB is also significantly associated with an increase in CD27- *M.tb*-specific CD4+ T cells, where evaluating CD27+ CD45RA- CD4+ IFN- $\gamma$ <sup>+</sup> T cells increases diagnostic accuracy of active TB vs. cured TB or LTBI even further (93). Indeed, the combination of different blood biomarkers – namely, CD27, CD45RA, and TNF – within the population of CD4<sup>+</sup> IFN- $\gamma$ <sup>+</sup> T cells provides a good acceptable diagnostic accuracy regarding active TB vs. LTBI with 92% sensitivity and 97% specificity while reducing the need to obtain a sputum sample (93). Notably, however, these improvements in immunodiagnosics are not POC and do not allow for the detection of DS- vs. DR-TB cases within a population of individuals that have active TB, regardless of their HIV status. As aforementioned, the field is still lacking in POCs to identify DR-TB and provide information about the drug resistance profile, particularly in high TB burden areas where DR-TB is more common.

Interestingly, there are studies in progress to determine when a LTBI case will progress to active TB. An expert consultation was convened by WHO in 2015 to develop target product profiles (TPPs) and an evaluation framework for tests aiming to predict progression from LTBI to active TB (94). In this context, indirect blood PCR-based biomarker tests looking at the expression of host immune response genes to *M.tb* infection are being developed and validated as diagnostic tools that can also predict progression from LTBI to active TB, targeting all forms of TB and patient populations (95). Supporting this, a systematic comparison study of 16 host-derived gene expression signatures (96) found that 7 out of 16 signatures predicted progression from LTBI to active TB disease 6 months prior to sputum conversion (e.g. incipient TB), indicating that some host-response-based diagnostics could be generalizable across diverse patient populations and thus, considered for clinical implementation (97).

## Immunodiagnosics of Active TB

One of the key pillars of the End TB strategy is based on early TB diagnosis (17, 98). In this regard, some time ago, a report generated together by WHO and the Foundation for Innovative New Diagnostics (FIND) identified four major TPPs, defining the targets and specifications that new diagnostic TB tests should meet (1): a POC non-sputum test capable of detecting all forms of TB (immunodiagnosis biomarker test); (2) a simple, low-cost POC test performed in clinical/rural settings (e.g. healthcare post) to screen and identify those who need further TB testing (triage test, immunodiagnosis or direct Ag-detection); (3) a POC sputum test to detect pulmonary TB to replace the widely used smear microscopy (the smear-replacement test); and (4) a rapid and efficient DST that can identify those in need of first-line drug treatment (a rapid DST test) (99, 100)

Despite the number of TB diagnostics available, there are still challenges to deploy these tests to urban and rural TB healthcare post and facilities (30, 101). Important parameters to consider in the development of POC diagnostics are, an easily accessible sample, rapid results, high sensitivity and specificity, and cost (less than USD \$4 in the location where the test is performed) (101). Currently, available POC diagnostics include the Determine™ lipoarabinomannan (TB-LAM) Ag test (antigen detection), FujiLAM TB test (antigen detection), LIODetect® TB-ST TB Rapid Test developed by LIONEX (antibody detection), and smartphone diagnostics discussed below.

Several POC TB diagnostics are based on the detection of a unique cell envelope component of *M.tb* complex, the mannose-capped lipoarabinomannan (ManLAM) (102). ManLAM is a lipoglycan antigen (Ag) present with a defined role in the survival of *M.tb* during infection (102–104). Specifically, the Determine™ TB-LAM Ag test (Abbott Rapid diagnostics, Abbott Park, IL USA) is a rapid lateral flow Ag-detection POC diagnostic TB test that uses non-invasive samples such as urine to detect undisclosed motifs on the *M.tb* ManLAM structure (104). This diagnostic test is considered to be a 'real' POC test, as it can be used and result read in the field within 25 minutes. This test can be useful to confirm active TB cases, specifically in PLWH, or with sputum smear negative results; however, the test has low sensitivity (52% sensitivity and 98% specificity) (104, 105). To improve upon the sensitivity of this test, our lab demonstrated a simple biochemical step using  $\alpha$ -mannosidase to treat the urine samples to cleave the mannose caps on the structure of LAM, providing an increased affinity for LAM antibodies to bind and recognize the epitopes (105). This additional step only added 15 minutes and \$0.50 to the cost (final \$3.50 per test). The FujiLAM TB test is another novel POC that detects LAM in the urine of patients with clinical symptoms of active TB disease (106). Specifically, the FujiLAM test detects the 5-methyl-thio-D-xylofuranose (MTX) motif found on the non-reducing terminal end of the ManLAM structure. The MTX motif reduces cross-reactivity with *M.tb* complex, thus it could be considered a rapid POC TB test that detects positive active TB cases (107, 108). The FujiLAM test has shown a superior diagnostic sensitivity in inpatients with HIV compared to the Determine™ TB-LAM Ag

test (70.4% vs. 42.3%) (109). The FujiLAM test also shows similar sensitivities (at 75%) in both PLWH and people without HIV infection (110). Furthermore, FujiLAM test shows a substantial higher sensitivity compared to the Determine™ TB-LAM Ag test for detecting extra-pulmonary TB in PLWH (111). Although both the Determine™ TB-LAM Ag and FujiLAM TB tests are rapid POC diagnostics, there is still uncertainty of their sensitivity among HIV negative patients and cannot differentiate between DS- vs. DR-TB (112).

Additionally, TB serological tests are used in mid and low income countries to detect the presence of antibodies for TB. One such serological test is the Anda-TB test developed by Anda Biologicals, which looks for the presence of either IgG, IgA, or IgM antibodies specific for the *M.tb* A60 antigen. Meta-analysis of the Anda-TB IgG test revealed a pooled sensitivity of 76% and specificity of 92% in individuals that were acid-fast bacilli (AFB) smear positive, and 59% sensitivity and 91% specificity in AFB smear negative individuals (113). Another TB POC is the LIODetect® TB-ST Rapid Test developed by LIONEX, which detects IgG, IgA and IgM antibodies to *M.tb* antigens in serum, plasma, or whole blood under 20 minutes with 65% sensitivity and 98% specificity (114).

Another aspect of POC diagnostics is the addition of simple adaptors to smartphones for reading results, simplifying the interphase required for TB diagnostics and improving accessibility given their use in daily life, high connectivity and functionality while being portable (115). Smartphones can be equipped with simple adaptors and apps that can be used to capture images for visualization and TB diagnosis (116). Another incentive for smartphones being added to the POC arsenal is that there are project initiatives such as Fair Phone and ARA that can provide low cost manufacturing on a large scale (115). Thus, new technologies and research efforts are imperative, especially in the context of POCs, to provide reliable results in a timely manner and at a low cost (100, 101).

On the light of immunodiagnosis specifically for DR-TB, nothing is developed or is known to be in the discovery pipeline. In this regard, metabolic studies in specimens isolated from DS- and DR-TB patients may bring some light into the discovery of biomarkers that are solely expressed when a person is infected with DR-*M.tb*. However, this seems not plausible. It will be challenging to identify a host biomarker panel to differentiate the drug resistant profile of the infecting *M.tb* strain. Even, if it is doable, a push back from the TB scientific community is expected, as evidences exists that immunodiagnostic tests can be inaccurate and thus, do not improve patient outcomes, and are considered suboptimal tests to be used for pulmonary and extrapulmonary active TB diagnosis in mid and low income countries with high TB burden.

## CONCLUSION

Despite recent and encouraging advances towards TB elimination, the ongoing COVID-19 pandemic disruption has undermined these achievements. Cases of *M.tb* infection

reactivation in people recovered from severe COVID-19 are reported (117, 118). The struggle of using recourses for TB diagnosis and care to manage the current demand on COVID-19 is expected to have an impact on TB control (119–121). One of the key aspects to target TB elimination is early TB diagnosis that needs affordable and high-sensitivity POC tests able to diagnose pulmonary and extra pulmonary TB in adults, children, and PLWH (100). To fill current gaps in DS- and DR-TB diagnosis, it is also imperative to develop novel sputum and non-sputum based POC or semi-POC (deployable in rural areas and health-post with minimal resources) diagnostic tests able to characterize drug resistance to improve proper TB care and long term TB treatment outcomes. We will need to consider revisiting phenotypic DST, as genotypic DST, despite its many advantages, has many social-economic barriers, most importantly the high cost that mid and low-income countries with high TB burden cannot afford, even with the assistance of WHO and the good faith of companies developing these technologies. In this context, even with WHO endorsement, national policy needs to be established to ensure test adoption, scale up, and implementation (122). At the end, the cost of supplies, the need of sophisticated technology requiring repeatedly calibrations and staff training; plus, the fact that current genotypic DST cannot identify resistance to current drugs (such as bedaquiline, delamanid and others), and misses the detection of some unknown mutations driving resistance to first line drugs, makes an improved phenotypic DST a need to cover a current global public health demand.

## REFERENCES

- Zweynert A. *Drug-Resistant TB Threatens to Kill 75 Million People by 2050, Cost \$16.7 Trillion*. London: Reuters (2022). Available at: <https://www.reuters.com/article/us-health-tuberculosis-economy-idUSKBN0MK00520150324>.
- TB Alliance. *Antimicrobial Resistance | TB Alliance*. New York: The TB Alliance (2021). Available at: <https://www.tballiance.org/why-new-tb-drugs/antimicrobial-resistance>.
- World Health Organization. *Impact of the COVID-19 Pandemic on TB Detection and Mortality in 2020* (2022). Available at: <https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020>.
- Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the Global Burden of Drug-Resistant Tuberculosis Avertable by a Post-Exposure Vaccine. *Nat Commun* (2021) 12(1):1–9. doi: 10.1038/s41467-020-20731-x
- O'Neill J. Review on Antimicrobial Resistance. In: *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations*. London: Review of Antimicrobial Resistance. Available at: [https://amr-review.org/sites/default/files/160525\\_Final paper\\_with cover.pdf](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf).
- World Health Organization. *Global Tuberculosis Report 2020*. (2020).
- World Health Organization. *Meeting Report of the WHO Expert Consultation on Drug-Resistant Tuberculosis Treatment Outcome Definitions, 17–19 November 2020*. Geneva: World Health Organization (2020). Available at: <https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis>.
- Hameed HMA, Islam MM, Chhotaray C, Wang C, Liu Y, Tan Y, et al. Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium Tuberculosis Strains. *Front Cell Infection Microbiol* (2018) 8. doi: 10.3389/fcimb.2018.00114

## LIMITATIONS

This narrative review is not a systematic review of the literature, and therefore it might unintentionally not include all published papers related to the topic discussed.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

## FUNDING

This study was partially supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) AI150445 to JT.

## ACKNOWLEDGMENTS

We thank Dr. Alberto García-Basteiro for his critical read. We thank the personnel of our labs and collaborators dedicated to TB research and specifically to the improvement of TB diagnosis in mid- and low-income countries with high TB burden.

- Akbar Velayati A, Farnia P, Reza Masjedi M. The Totally Drug Resistant Tuberculosis (TDR-Tb). *Int J Clin Exp Med* (2013) 6(4):307–9.
- World Health Organization. *Tuberculosis: Totally drug-resistant TB*. Available at: <https://www.who.int/news-room/q-a-detail/tuberculosis-totally-drug-resistant-tb>.
- Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, et al. Extensively Drug-Resistant Tuberculosis, Italy and Germany. *Emerg Infect Dis* (2007) 13(5):780–2. doi: 10.3201/eid1305.070200
- Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics. *Cell* (2007) 130(5):797–810. doi: 10.1016/j.cell.2007.06.049
- Nguyen L. Antibiotic Resistance Mechanisms in M. Tuberculosis: An Update. *Arch Toxicol* (2016) 90(7):1585–604. doi: 10.1007/s00204-016-1727-6
- Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, Regional, and National Age-Sex Specific Mortality for 264 Causes of Death, 1980–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. *Lancet (London England)* (2017) 390(10100):1151–210. doi: 10.1016/S0140-6736(17)32152-9
- Reichmuth ML, Hömke R, Zürcher K, Sander P, Avihingsanon A, Collantes J, et al. Natural Polymorphisms in Mycobacterium Tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. *Antimicrob Agents Chemother* (2020) 64(11):e00513–20. doi: 10.1128/AAC.00513-20
- Zürcher K, Ballif M, Fenner L, Borrell S, Keller P, Gnokoro J, et al. Drug Susceptibility Testing and Mortality in Patients Treated for Tuberculosis in High-Burden Countries: A Multicentre Cohort Study. *Lancet Infect Dis* (2019) 19(3):298–307. doi: 10.1016/S1473-3099(18)30673-X
- World Health Organization. *The End TB Strategy [Internet]*. World Health Organization. Geneva: World Health Organization (2015). Available at: [http://www.who.int/tb/post2015\\_strategy/en/%0Ahttps://www.who.int/tb/post2015\\_strategy/en/%0Ahttp://www.who.int/tb/post2015\\_strategy/en/](http://www.who.int/tb/post2015_strategy/en/%0Ahttps://www.who.int/tb/post2015_strategy/en/%0Ahttp://www.who.int/tb/post2015_strategy/en/).



18. World Health Organization. Consolidated Guidelines on Tuberculosis. In: *Module 3: Diagnosis. Rapid Diagnostics for Tuberculosis Detection*. Geneva: WHO (2021). p. 164 p. Available at: <https://www.who.int/publications/item/9789240029415>.
19. Gilpin C, Korobitsyn A, Weyer K. Current Tools Available for the Diagnosis of Drug-Resistant Tuberculosis. *Ther Adv Infect Dis* (2016) 3(6):145–51. doi: 10.1177/2049936116673553
20. World Health Organization. *Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis*. Geneva: World Health Organization (2018). Available at: [https://www.who.int/tb/publications/2018/WHO\\_technical\\_drug\\_susceptibility\\_testing/en/#.X8-ZD\\_qgkHg.mendeley](https://www.who.int/tb/publications/2018/WHO_technical_drug_susceptibility_testing/en/#.X8-ZD_qgkHg.mendeley).
21. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, et al. Mycobacteria: Laboratory Methods For Testing Drug Sensitivity And Resistance. *Bull World Health Organ* (1963) 29(5):565–78.
22. World Health Organization. *WHO Treatment Guidelines for Drug-Resistant Tuberculosis*. Geneva: WHO (2018). Available at: <http://apps.who.int/iris/handle/10665/250125>.
23. Hu P, Zhang H, Fleming J, Zhu G, Zhang S, Wang Y, et al. Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples From a Referral Hospital in Hunan, China. *J Clin Microbiol* (2019) 57(4):e01707–18. doi: 10.1128/JCM.01707-18
24. Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, et al. Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF in Swaziland. *N Engl J Med* (2015) 372(12):1181–2. doi: 10.1056/NEJMc1413930
25. Ardizzoni E, Ariza E, Mulengwa D, Mpala Q, de la Tour R, Maphalala G, et al. Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium Tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests. *Antimicrob Agents Chemother* (2021) 65(6):e02263–20. doi: 10.1128/AAC.02263-20
26. Van Rie A, Mellet K, John MA, Scott L, Page-Shipp L, Dansey H, et al. False-Positive Rifampicin Resistance on Xpert® MTB/RIF: Case Report and Clinical Implications. *Int J Tuberc Lung Dis* (2012) 16(2):206–8. doi: 10.5588/ijtld.11.0395
27. Ocheretina O, Byrt E, Mabou MM, Royal-Mardi G, Merveille YM, Rouzier V, et al. False-Positive Rifampin Resistant Results With Xpert MTB/RIF Version 4 Assay in Clinical Samples With a Low Bacterial Load. *Diagn Microbiol Infect Dis* (2016) 85(1):53–5. doi: 10.1016/j.diagmicrobio.2016.01.009
28. Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, et al. False-Positive Xpert MTB/RIF Results in Retested Patients With Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. *J Clin Microbiol* (2018) 56(3):e01696–17. doi: 10.1128/JCM.01696-17
29. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. False-Positive Xpert® MTB/RIF Assays in Previously Treated Patients: Need for Caution in Interpreting Results. *Int J Tuberc Lung Dis* (2014) 18(7):876–78. doi: 10.5588/ijtld.13.0853
30. Toit K, Mitchell S, Balabanova Y, Evans CA, Kummik T, Nikolayevskyy V, et al. The Colour Test for Drug Susceptibility Testing of Mycobacterium Tuberculosis Strains. *Int J Tuberc Lung Dis* (2012) 16(8):1113–8. doi: 10.5588/ijtld.11.0609
31. Mekonnen B, Mihret A, Getahun M, Hailu T, Sidiki S, V. Kelley H, et al. Evaluation of the Tuberculosis Culture Color Plate Test for Rapid Detection of Drug Susceptible and Drug-Resistant Mycobacterium Tuberculosis in a Resource-Limited Setting, Addis Ababa, Ethiopia. *PLoS One* (2019) 14(5):e0215679. doi: 10.1371/journal.pone.0215679
32. Shibabaw A, Gelaw B, Kelley H, Balada-Llasat JM, Evans C, Wang S-H, et al. Accuracy of the Color Plate Micro-Colony Detection for the Diagnosis of Mycobacterium Tuberculosis Complex in Northwest Ethiopia. *Tuberculosis* (2019) 114:54–60. doi: 10.1016/j.tube.2018.11.007
33. Shibabaw A, Gelaw B, Gebreyes W, Robinson R, Wang S-H, Tessema B. The Burden of Pre-Extensively and Extensively Drug-Resistant Tuberculosis Among MDR-TB Patients in the Amhara Region, Ethiopia. *PLoS One* (2020) 15(2):e0229040. doi: 10.1371/journal.pone.0229040
34. Zhang A, Jumbe E, Krysiak R, Sidiki S, Kelley HV, Chemey EK, et al. Low-Cost Diagnostic Test for Susceptible and Drug-Resistant Tuberculosis in Rural Malawi. *Afr J Lab Med* (2018) 7:1–6. doi: 10.4102/ajlm.v7i1.690
35. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, De Rijk WB, et al. Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard. *J Clin Microbiol* (2013) 51(8):2633–40. doi: 10.1128/JCM.00553-13
36. Vilchèze C, Wang F, Arai M, Hazbón MH, Colangeli R, Kremer L, et al. Transfer of a Point Mutation in Mycobacterium Tuberculosis inhA Resolves the Target of Isoniazid. *Nat Med* (2006) 12(9):1027–9. doi: 10.1038/nm1466
37. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. Etha, Inha, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium Tuberculosis Isolates. *Antimicrob Agents Chemother* (2003) 47(12):3799–805. doi: 10.1128/AAC.47.12.3799-3805.2003
38. Machado D, Perdigão J, Ramos J, Couto I, Portugal I, Ritter C, et al. High-Level Resistance to Isoniazid and Ethionamide in Multidrug-Resistant Mycobacterium Tuberculosis of the Lisboa Family is Associated With inhA Double Mutations. *J Antimicrob Chemother* (2013) 68(8):1728–32. doi: 10.1093/jac/dkt090
39. Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udawadia Z, et al. Defining Multidrug-Resistant Tuberculosis: Correlating GenoType MTBDRplus Assay Results With Minimum Inhibitory Concentrations. *Diagn Microbiol Infect Dis* (2015) 82(1):49–53. doi: 10.1016/j.diagmicrobio.2015.01.009
40. Van Deun A, Decroo T, Maug AKJ, Hossain MA, Gumusboga M, Mulders W, et al. The Perceived Impact of Isoniazid Resistance on Outcome of First-Line Rifampicin-Through-out Regimens is Largely Due to Missed Rifampicin Resistance. *PLoS One* (2020) 15(5):e0233500. doi: 10.1371/journal.pone.0233500
41. Cohen KA, Manson AL, Desjardins CA, Abeel T, Earl AM. Deciphering Drug Resistance in Mycobacterium Tuberculosis Using Whole-Genome Sequencing: Progress, Promise, and Challenges. *Genome Med* (2019) 11(1):1–18. doi: 10.1186/s13073-019-0660-8
42. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic Mutations Associated With Isoniazid Resistance in Mycobacterium Tuberculosis: A Systematic Review. *PLoS One* (2015) 10(3):e0119628. doi: 10.1371/journal.pone.0119628
43. Tamilzhalagan S, Shanmugam S, Selvaraj A, Suba S, Suganthi C, Moonan PK, et al. Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates—Chennai, India, 2013–2016. *Front Microbiol* (2021) 12:3364. doi: 10.3389/fmicb.2021.720436
44. MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG, Denking CM, et al. Advances in Molecular Diagnosis of Tuberculosis. *J Clin Microbiol* (2020) 58(10):e01582–19. doi: 10.1128/JCM.01582-19
45. Xie YL, Chakravorty S, Armstrong DT, Hall SL, Song T, Yuan X, et al. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. *N Engl J Med* (2017) 377(11):1043–54. doi: 10.1056/NEJMoa1614915
46. Van RA, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert® MTB/RIF for Point-of-Care Diagnosis of TB in High-HIV Burden, Resource-Limited Countries: Hype or Hope? *Expert Rev Mol Diagn* (2010) 10(7):937–46. doi: 10.1586/erm.10.67
47. Evans CA. GeneXpert—A Game-Changer for Tuberculosis Control? *PLoS Med* (2011) 8(7):e1001064. doi: 10.1371/journal.pmed.1001064
48. Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, et al. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results? *Clin Infect Dis* (2016) 62(8):995–1001. doi: 10.1093/cid/civ1223
49. Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al. Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in Children: A Systematic Review and Meta-Analysis. *Lancet Respir Med* (2015) 3(6):451–61. doi: 10.1016/S2213-2600(15)00095-8
50. Theron G, Peter J, Van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. *Am J Respir Crit Care Med* (2011) 184(1):132–40. doi: 10.1164/rccm.201101-0056OC
51. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, et al. Xpert MTB/RIF Versus Sputum Microscopy as the Initial Diagnostic Test for Tuberculosis: A Cluster-Randomised Trial Embedded in South African Roll-Out of Xpert MTB/RIF. *Lancet Glob Heal* (2015) 3(8):e450–7. doi: 10.1016/S2214-109X(15)00100-X
52. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic With

- High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial. *PLoS Med* (2014) 11(11):e1001760. doi: 10.1371/journal.pmed.1001760
53. World Health Organization. *WHO Consolidated Guidelines on Tuberculosis Rapid Diagnostics for Tuberculosis Detection, 2021 Update*. Geneva: World Health Organization (2021).
  54. World Health Organization. *WHO Consolidated Guidelines on Tuberculosis. Module 3: Diagnosis – Rapid Diagnostics for Tuberculosis Detection Web Annex 2. GRADE Profiles*. Geneva: World Health Organization (2021).
  55. Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B, et al. Evaluation of Genotype MTBDRplus VER 2.0 Line Probe Assay for the Detection of MDR-TB in Smear Positive and Negative Sputum Samples. *BMC Infect Dis* (2017) 17(1):1–8. doi: 10.1186/s12879-017-2389-6
  56. Singla N, Satyanarayana S, Sachdeva KS, Van Den Bergh R, Reid T, Tayler-Smith K, et al. Impact of Introducing the Line Probe Assay on Time to Treatment Initiation of MDR-TB in Delhi, India. *PLoS One* (2014) 9(7):e102989. doi: 10.1371/journal.pone.0102989
  57. Pütová I, Havelková M, Švandová E. Application of the Gen-Probe Amplified MTD Test (Mycobacterium Tuberculosis Direct Test) in the Diagnostics of Tuberculosis. *Cent Eur J Public Health* (1996) 4(2):91–5.
  58. Govindaswamy A, Sakthi D, Pai R, Jayaseelan L, Michael JS. Pyrosequencing: A Rapid and Effective Sequencing Method to Diagnose Drug-Resistant Tuberculosis. *J Med Microbiol* (2018) 67(9):1212–6. doi: 10.1099/jmm.0.000669
  59. Wu CW, Wu YK, Lan CC, Yang MC, Dong TQ, Tzeng IS, et al. Impact of Nucleic Acid Amplification Test on Pulmonary Tuberculosis Notifications and Treatments in Taiwan: A 7-Year Single-Center Cohort Study. *BMC Infect Dis* (2019) 19(1):1–7. doi: 10.1186/s12879-019-4358-8
  60. Goodwin S, McPherson JD, McCombie WR. Coming of Age: Ten Years of Next-Generation Sequencing Technologies. *Nat Rev Genet* (2016) 17(6):333–51. doi: 10.1038/nrg.2016.49
  61. Papaventsis D, Casali N, Kontsevaya I, Drobniewski F, Cirillo DM, Nikolayevskyy V. Whole Genome Sequencing of Mycobacterium Tuberculosis for Detection of Drug Resistance: A Systematic Review. *Clin Microbiol Infect* (2017) 23(2):61–8. doi: 10.1016/j.cmi.2016.09.008
  62. Gygli SM, Keller PM, Ballif M, Blöchliger N, Hönke R, Reinhard M, et al. Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium Tuberculosis. *Antimicrob Agents Chemother* (2019) 63(4):e02175–18. doi: 10.1128/AAC.02175-18
  63. Luo Y, Suliman S, Asgari S, Amariuta T, Baglaenko Y, Martínez-Bonet M, et al. Early Progression to Active Tuberculosis is a Highly Heritable Trait Driven by 3q23 in Peruvians. *Nat Commun* (2019) 10(1):3765. doi: 10.1038/s41467-019-11664-1
  64. Farhat MR, Freschi L, Calderon R, Ioerger T, Snyder M, Meehan CJ, et al. GWAS for Quantitative Resistance Phenotypes in Mycobacterium Tuberculosis Reveals Resistance Genes and Regulatory Regions. *Nat Commun* (2019) 10(1):1–11. doi: 10.1038/s41467-019-10110-6
  65. Pankhurst LJ, del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, et al. Rapid, Comprehensive, and Affordable Mycobacterial Diagnosis With Whole-Genome Sequencing: A Prospective Study. *Lancet Respir Med* (2016) 4(1):49–58. doi: 10.1016/S2213-2600(15)00466-X
  66. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A Blood RNA Signature for Tuberculosis Disease Risk: A Prospective Cohort Study. *Lancet* (2016) 387(10035):2312–22. doi: 10.1016/S0140-6736(15)01316-1
  67. World Health Organization. The Use of Loop-Mediated Isothermal Amplification (TB-LAMP) for the Diagnosis of Pulmonary Tuberculosis: Policy Guidance. In: *WHO Library Cataloguing-In-Publication Data*. Geneva: World Health Organization (2016). Available at: <https://apps.who.int/iris/bitstream/handle/10665/249154/9789241511186-eng.pdf>.
  68. World Health Organization. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-Tb). In: *Policy Statement*. Geneva: World Health Organization (2008). Available at: <http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:molecular+line+probe+assays+for+rapid+screening+of+patients+at+risk+of+multidrug-resistant+tuberculosis+policy+statement#0>.
  69. World Health Organization. *Meeting Report of a Technical Expert Consultation: Non-Inferiority Analysis of Xpert MTB/RIF Ultra Compared to Xpert MTB/RIF* (2017). Available at: <http://apps.who.int/bookorders>.
  70. Taylor Z, Nolan CM, Blumberg HM. Controlling Tuberculosis in the United States. Recommendations From the American Thoracic Society, {CDC}, and the Infectious Diseases Society of America. In: *{MMWR} Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers for Disease Control*, vol. Vol. 54. Atlanta: MMWR Morb Mortal Wkly Rep (2005). p. 1–81. Available at: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L41590859>.
  71. Restrepo BI, Camerlin AJ, Rahbar MH, Wang W, Restrepo MA, Zarate I, et al. Cross-Sectional Assessment Reveals High Diabetes Prevalence Among Newly-Diagnosed Tuberculosis Cases. *Bull World Health Organ* (2011) 89(5):352–9. doi: 10.2471/BLT.10.085738
  72. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma Interferon Release Assays for Detection of Mycobacterium Tuberculosis Infection. *Clin Microbiol Rev* (2014) 27(1):3–20. doi: 10.1128/CMR.00034-13
  73. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, et al. Correlates of Tuberculosis Risk: Predictive Biomarkers for Progression to Active Tuberculosis. *Eur Respir J* (2016) 48(6):1751–63. doi: 10.1183/13993003.01012-2016
  74. Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MHA, Akbar AN. Mantoux Test as a Model for a Secondary Immune Response in Humans. *Immunol Lett* (2006) 107(2):93–101. doi: 10.1016/j.imlet.2006.08.002
  75. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-Gamma Release Assays and Childhood Tuberculosis: Systematic Review and Meta-Analysis. *Int J Tuberc Lung Dis* (2011) 15(8):1018–32. doi: 10.5588/ijtld.10.0631
  76. Santin M, Muñoz L, Rigau D. Interferon- $\gamma$  Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. *PLoS One* (2012) 7(3):e32482. doi: 10.1371/journal.pone.0032482
  77. Scordo JM, Aguillón-Durán GP, Ayala D, Quirino-Cerrillo AP, Rodríguez-Reyna E, Joya-Ayala M, et al. Interferon Gamma Release Assays for Detection of Latent Mycobacterium Tuberculosis in Older Hispanic People. *Int J Infect Dis* (2021) 111:85–91. doi: 10.1016/j.ijid.2021.08.014
  78. Scherrer S, Landolt P, Friedel U, Stephan R. Distribution and Expression of Esat-6 And cfp-10 in non-Tuberculous Mycobacteria Isolated From Lymphnodes of Slaughtered Cattle in Switzerland. *J Vet Diagn Invest* (2019) 31(2):217. doi: 10.1177/1040638718824074
  79. Wang MS, Wang JL, Wang XF. The Performance of Interferon-Gamma Release Assay in Nontuberculous Mycobacterial Diseases: A Retrospective Study in China. *BMC Pulm Med* (2016) 16(1):163. doi: 10.1186/s12890-016-0320-3
  80. Arend SM, De Haas P, Leyten E, Rosenkrands I, Rigouts L, Andersen P, et al. ESAT-6 and CFP-10 in Clinical Versus Environmental Isolates of Mycobacterium Kansasii. *J Infect Dis* (2005) 191(8):1301–10. doi: 10.1086/428950
  81. WHO. Development of a Target Product Profile (TPP) and a Framework for Evaluation for a Test for Predicting Progression From Tuberculosis Infection to Active Disease 2017 WHO Collaborating Centre for the Evaluation of New Diagnostic Technologies. In: *Analytical and Bioanalytical Chemistry*, vol. Vol. 414. . Deutschland GmbH: Springer Science and Business Media (2017). Available at: <https://link.springer.com/article/10.1007/s00216-021-03702-z>.
  82. Yao X, Liu Y, Liu Y, Liu W, Ye Z, Zheng C, et al. Multiplex Analysis of Plasma Cytokines/Chemokines Showing Different Immune Responses in Active TB Patients, Latent TB Infection and Healthy Participants. *Tuberculosis* (2017) 107:88–94. doi: 10.1016/j.tube.2017.07.013
  83. Wang S, Li Y, Shen Y, Wu J, Gao Y, Zhang S, et al. Screening and Identification of a Six-Cytokine Biosignature for Detecting TB Infection and Discriminating Active From Latent TB. *J Transl Med* (2018) 16(1):1–13. doi: 10.1186/s12967-018-1572-x
  84. Kunnath-Velayudhan S, Gennaro ML. Immunodiagnosis of Tuberculosis: A Dynamic View of Biomarker Discovery. *Clin Microbiol Rev* (2011) 24(4):792. doi: 10.1128/CMR.00014-11
  85. Chegou NN, Sutherland JS, Namuganga AR, Corstjens PLAM, Geluk A, Gebremichael G, et al. Africa-Wide Evaluation of Host Biomarkers in QuantiFERON Supernatants for the Diagnosis of Pulmonary Tuberculosis. *Sci Rep* (2018) 8(1):2675. doi: 10.1038/s41598-018-20855-7



86. Mupfumi L, Mpande CAM, Reid T, Moyo S, Shin SS, Zetola N, et al. Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment. *Pathogens* (2020) 9(3):180. doi: 10.3390/pathogens9030180
87. Tippalagama R, Singhanian A, Dubelko P, Lindestam Arlehamn CS, Crinklaw A, Pomaznoy M, et al. HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. *J Immunol* (2021) 207(2):523–33. doi: 10.4049/jimmunol.2100011
88. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, et al. Biomarkers on Patient T Cells Diagnose Active Tuberculosis and Monitor Treatment Response. *J Clin Invest* (2015) 125(5):1827–38. doi: 10.1172/JCI77990
89. Ahmed MIM, Ntinginya NE, Kibiki G, Mtafya BA, Semvua H, Mpagama S, et al. Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy. *Front Immunol* (2018) 9:2247. doi: 10.3389/fimmu.2018.02247
90. Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, et al. Combined Use of Mycobacterium Tuberculosis-Specific CD4 and CD8 T-Cell Responses is a Powerful Diagnostic Tool of Active Tuberculosis. *Clin Infect Dis* (2015) 60(3):432–7. doi: 10.1093/cid/ciu795
91. Wilkinson KA, Oni T, Gideon HP, Goliath R, Wilkinson RJ, Riou C. Activation Profile of Mycobacterium Tuberculosis-Specific CD4(+) T Cells Reflects Disease Activity Irrespective of HIV Status. *Am J Respir Crit Care Med* (2016) 193(11):1307–10. doi: 10.1164/rccm.201601-0116LE
92. Riou C, Berkowitz N, Goliath R, Burgers WA, Wilkinson RJ. Analysis of the Phenotype of Mycobacterium Tuberculosis-Specific CD4+ T Cells to Discriminate Latent From Active Tuberculosis in HIV-Uninfected and HIV-Infected Individuals. *Front Immunol* (2017) 8. doi: 10.3389/fimmu.2017.00968
93. Xu F, Zhang H, Si X, Chen J, Chen Y, Cui X, et al. Assessment of CD27 Expression on T-Cells as a Diagnostic and Therapeutic Tool for Patients With Smear-Negative Pulmonary Tuberculosis. *BMC Immunol* (2021) 22(1):41. doi: 10.1186/s12865-021-00430-y
94. WHO. *Consensus Meeting Report: Development of a Target Product Profile (TPP) and a Framework for Evaluation for a Test for Predicting Progression From Tuberculosis Infection to Active Disease*. Geneva: WHO Publications (2017). Available at: <https://www.who.int/publications/i/item/WHO-HTM-TB-2017.18>.
95. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, et al. Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. *Front Microbiol* (2019) 10. doi: 10.3389/fmicb.2019.01441
96. Warsinske H, Vashisht R, Khatri P. Host-Response-Based Gene Signatures for Tuberculosis Diagnosis: A Systematic Comparison of 16 Signatures. *PLoS Med* (2019) 16(4):e1002786. doi: 10.1371/journal.pmed.1002786
97. Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, et al. Discovery and Validation of a Prognostic Proteomic Signature for Tuberculosis Progression: A Prospective Cohort Study. *PLoS Med* (2019) 16(4):e1002781. doi: 10.1371/journal.pmed.1002781
98. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. Who's New End TB Strategy. *Lancet* (2015) 385(9979):1799–801. doi: 10.1016/S0140-6736(15)60570-0
99. World Health Organization. *High Priority Target Product Profiles for New Tuberculosis Diagnostics: Report of a Consensus Meeting, 28–29 April 2014, Geneva, Switzerland*. Geneva: WHO Publications (2014). Available at: <https://apps.who.int/iris/handle/10665/135617>.
100. García JI, Allué-Guardia A, Tampi RP, Restrepo BI, Torrelles JB. New Developments and Insights in the Improvement of Mycobacterium Tuberculosis Vaccines and Diagnostics Within the End TB Strategy. *Curr Epidemiol Rep* (2021) 8(2):33–45. doi: 10.1007/s40471-021-00269-2
101. García-Basteiro AL, DiNardo A, Saavedra B, Silva DR, Palmero D, Gegia M, et al. Point of Care Diagnostics for Tuberculosis. *Pulmonology* (2018) 24(2):73–85. doi: 10.1016/j.rppnen.2017.12.002
102. Turner J, Torrelles JB. Mannose-Capped Lipoarabinomannan in Mycobacterium Tuberculosis Pathogenesis. *Pathog Dis* (2018) 76(4):1–15. doi: 10.1093/femspd/fty026
103. Torrelles JB, Knaup R, Kolareth A, Slepshkina T, Kaufman TM, Kang P, et al. Identification of Mycobacterium Tuberculosis Clinical Isolates With Altered Phagocytosis by Human Macrophages Due to a Truncated Lipoarabinomannan. *J Biol Chem* (2008) 283(46):31417–28. doi: 10.1074/jbc.M806350200
104. Lawn SD, Gupta-Wright A. Detection of Lipoarabinomannan (LAM) in Urine is Indicative of Disseminated TB With Renal Involvement in Patients Living With HIV and Advanced Immunodeficiency: Evidence and Implications. *Trans R Soc Trop Med Hyg* (2016) 110(3):180–5. doi: 10.1093/trstmh/trw008
105. García JI, Kelley HV, Meléndez J, de León RAA, Castillo A, Sidiki S, et al. Improved Alere Determine Lipoarabinomannan Antigen Detection Test for the Diagnosis of Human and Bovine Tuberculosis by Manipulating Urine and Milk. *Sci Rep* (2019) 9(1):18012. doi: 10.1038/s41598-019-54537-9
106. Fujifilm Global. *Fujifilm and FIND Sign Development Contract to Develop Highly Sensitive Rapid Tuberculosis Diagnosis Kit for Developing Countries* (2016). Available at: <https://global.fujifilm.com/en/>.
107. Turnbull WB, Shimizu KH, Chatterjee D, Homans SW, Treumann A. Identification of the 5-Methylthiopentoseyl Substituent in Mycobacterium Tuberculosis Lipoarabinomannan. *Angew Chemie Int Ed* (2004) 43(30):3918–22. doi: 10.1002/anie.200454119
108. Treumann A, Xidong F, McDonnell L, Derrick PJ, Ashcroft AE, Chatterjee D, et al. 5-Methylthiopentose: A New Substituent on Lipoarabinomannan in Mycobacterium Tuberculosis. *J Mol Biol* (2002) 316(1):89–100. doi: 10.1006/jmbi.2001.5317
109. Broger T, Reipold I, Ongarello S, Mbchb S, Mbchb S, Mbchb AW, et al. Novel Lipoarabinomannan Point-of-Care Tuberculosis Test for People With HIV: A Diagnostic Accuracy Study. *Artic Lancet Infect Dis* (2019) 19:852–61. doi: 10.1016/S1473-3099(19)30001-5
110. Muyoyeta M, Kerkhoff AD, Chilukutu L, Moreau E, Schumacher SG, Ruhwald M. Diagnostic Accuracy of a Novel Point-of-Care Urine Lipoarabinomannan Assay for the Detection of Tuberculosis Among Adult Outpatients in Zambia: A Prospective Cross-Sectional Study. *Eur Respir J* (2021) 58:2003999. doi: 10.1183/13993003.03999-2020
111. Kerkhoff AD, Sossen B, Schutz C, Reipold EI, Trollip A, Moreau E, et al. Diagnostic Sensitivity of SILVAMP TB-LAM (FujiLAM) Point-of-Care Urine Assay for Extra-Pulmonary Tuberculosis in People Living With HIV. *Eur Respir J* (2020) 55(2):1901259. doi: 10.1183/13993003.01259-2019
112. Luisa P, Ruben M, Fatima Z, Robyn A, Neal S, Michael H, et al. Urine Lipoarabinomannan Glycan in HIV-Negative Patients With Pulmonary Tuberculosis Correlates With Disease Severity. *Sci Transl Med* (2017) 9(420):eaal2807. doi: 10.1126/scitranslmed.aal2807
113. Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, et al. Commercial Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis. *PLoS Med* (2011) 8(8):e1001062. doi: 10.1371/journal.pmed.1001062
114. LIONEX and LIONEX. *LIODetect TB-ST Tuberculosis Rapid Test*. (2019).
115. Hernández-Neuta I, Neumann F, Brightmeyer J, Ba Tis T, Madaboosi N, Wei Q, et al. Smartphone-Based Clinical Diagnostics: Towards Democratization of Evidence-Based Health Care. *J Intern Med* (2019) 285(1):19–39. doi: 10.1111/joim.12820
116. Alawsi T, Al-Bawi Z. A Review of Smartphone Point-of-Care Adapter Design. *Eng Rep* (2019) 1(2):e12039. doi: 10.1002/eng.2.12039
117. Aguilón-Durán GP, Prieto-Martínez E, Ayala D, García J, Thomas JM, García JI, et al. COVID-19 and Chronic Diabetes: The Perfect Storm for Reactivation Tuberculosis?: A Case Series. *J Med Case Rep* (2021) 15(1):621. doi: 10.1186/s13256-021-03193-7
118. Yadav S, Rawal G. Primary Multidrug-Resistant Pulmonary Tuberculosis With a Concomitant COVID-19 Infection in an Indian Female- World's First Case of its Type in This Current Pandemic. *J Fam Med Prim Care* (2021) 10(10):3922. doi: 10.4103/jfmpc.jfmpc\_225\_21
119. Malik AA, Hussain H, Maniar R, Safdar N, Mohiuddin A, Riaz N, et al. Integrated Tuberculosis and COVID-19 Activities in Karachi and Tuberculosis Case Notifications. *Trop Med Infect Dis* (2022) 7(1):12. doi: 10.3390/tropicalmed7010012
120. Min J, Ko Y, Kim HW, Koo H-K, Oh JY, Jeong Y-J, et al. Increased Healthcare Delays in Tuberculosis Patients During the First Wave of

- COVID-19 Pandemic in Korea: A Nationwide Cross-Sectional Study. *J Korean Med Sci* (2022) 37(3):e20. doi: 10.3346/jkms.2022.37.e20
121. Lewer D, Mulchandani R, Roche A, Cosgrove C, Anderson C. Why has the Incidence of Tuberculosis Not Reduced in London During the COVID-19 Pandemic? *Lancet Respir Med* (2022) 10:231–3. doi: 10.1016/S2213-2600(22)00012-1
122. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME, et al. Which New Diagnostics for Tuberculosis, and When? *J Infect Dis* (2012) 205 (suppl\_2):S191–8. doi: 10.1093/infdis/jis188

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Yusoof, García, Schami, Garcia-Vilanova, Kelley, Wang, Rendon, Restrepo, Yotebieng and Torrelles. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*